Brain cancer trial tests Chemo-First strategy to spare patients from radiation side effects
NCT ID NCT05331521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new chemotherapy combination (CETEG) for adults with a slow-growing brain tumor called oligodendroglioma. The goal is to see if starting with chemo alone can delay or avoid radiation therapy, which can cause long-term cognitive and quality-of-life problems. The study will compare this approach to the current standard of chemoradiation, measuring how long patients live without significant functional decline.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CETEG (lomustine and temozolomide)
- What this could lead to
- If successful, this approach could delay the need for brain radiation, preserving cognitive function and quality of life for people with oligodendroglioma.
- What could go wrong
- This is an early-stage trial with 406 participants, and the new chemo combo may not be as effective as standard treatment. There is also a risk of side effects from the chemotherapy drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGODENDROGLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charité, University Medicine Berlin, Neurosurgery
RECRUITINGBerlin, 10117, Germany
-
Chemnitz Hospital, Neurosurgery
RECRUITINGChemnitz, 09116, Germany
-
Helios Hospital Schwerin, Neurosurgery
RECRUITINGSchwerin, 19049, Germany
-
Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic
RECRUITINGBochum, 44892, Germany
-
University Clinic Muehlenkreis, Minden
RECRUITINGMinden, 32429, Germany
-
University Hospital Bonn, Neurology Clinic
RECRUITINGBonn, 53127, Germany
-
University Hospital Cologne, Neurosurgery
RECRUITINGCologne, 50937, Germany
-
University Hospital Duesseldorf, Neurooncology
RECRUITINGDüsseldorf, 40225, Germany
-
University Hospital Frankfurt, Neurooncology
RECRUITINGFrankfurt, 60528, Germany
-
University Hospital Göttingen, Neurosurgery
RECRUITINGGöttingen, 37075, Germany
-
University Hospital Heidelberg, Department of Neurooncology
RECRUITINGHeidelberg, Baden-Wurttemberg, 69120, Germany
-
University Hospital Leipzig, Radiation Therapy
RECRUITINGLeipzig, 04103, Germany
-
University Hospital Mannheim, Neurology Clinic
RECRUITINGMannheim, 68167, Germany
-
University Hospital Regensburg, Neurology Clinic
RECRUITINGRegensburg, 93053, Germany
-
University Hospital Saarland, Neurosurgery
RECRUITINGHomburg, 66421, Germany
-
University Hospital Tuebingen, Neurooncology
RECRUITINGTübingen, 72076, Germany
-
University Hospital Wuerzburg, Neurosurgery
RECRUITINGWürzburg, 97080, Germany
-
University Hospital of Jena, Neurosurgery
RECRUITINGJena, 07747, Germany
-
University Hospital rechts der Isar, Radiation Oncology
RECRUITINGMunich, 81675, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted pill aims to stall a common brain Tumor's growth
- New hope for brain tumor patients when standard drug fails
- Artificial intelligence reads brain scans to detect hidden tumor type
- Brain tumor study probes how income and community shape health
- New hope for young brain cancer patients: targeted drug combo enters phase 2 trial
- Brain radiation showdown: proton vs. photon – which saves your mind?